PDCD1 and neoplasm: The antitumor efficacy of PD1/PDL1 blockade depends on the existence of antigen-specific T cell reactivity in TME, which requires potential tumor rejection antigens presented by dendritic cells (DCs) to cross-priming CD8+ T cells and triggering subsequent antitumor activity (Mempel et al., 2004).